Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

The Canadian Correction……We Called It!

Mar 13, 2017 • 11:46 AM EDT
Untitled design (33).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

On the last day of February, as valuations were looking frothy, we sounded the alarm on Canadian cannabis stocks and decreased our leverage to the sector.

Although this decision did not initially sit well with Mushroomstocks Premium Members, those who listened were quite pleased. As we did not completely exit the Canadian cannabis sector, we were able to realize gains on our largest holdings (Aphria, Canopy, OrganiGram and Aurora). 

When this decision was announced, we highlighted our intention to re-invest in these companies and explained that these moves were part of our overall investing strategy (i.e. accepting gains over 100% or greater).

A Play that Pays

During the following week, while Canopy, OrganiGram and Aurora, plunged 16%, 23%, and 13%, respectively Aphria fell less than 10%.

On Wednesday, Mushroomstocks commenced its reinvestment strategy and re-entered into Aphria (APHQF) and Canopy Growth Corp (TWMJF). We created positions that equal 20% of our total planned investments and so far, these investments have proven to be profitable.

Patience is Key to Investing

Since one of the most important traits an investor needs to have to be successful is patience we are taking a patient approach with our reinvestment strategy

We employ several important strategies into our overarching investment strategy and this has proven beneficial to Mushroomstocks Premium Members as they are up over 1,000% during the last year.

Outlook is Bright

Despite these volatile moves lower, we continue to see significant upside to several Canadian cannabis investments. Investors can access this premium data by becoming a Mushroomstocks Premium Member today.

Sign up and save 10% on monthly memberships with the code “upgrade10” (all lower case).

Save 50% on annual memberships with the code “annual” (all lower case).

Important Investor Disclosures

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional adviceregarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report


Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.